JAMA : the journal of the American Medical Association
-
Randomized Controlled Trial Multicenter Study
Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial.
Pediatric-onset Crohn disease is more aggressive than adult-onset disease, has high rates of resistance to existing drugs, and can lead to permanent impairments. Few trials have evaluated new drugs for refractory Crohn disease in children. ⋯ In children and adolescents with refractory Crohn disease, thalidomide compared with placebo resulted in improved clinical remission at 8 weeks of treatment and longer-term maintenance of remission in an open-label follow-up. These findings require replication to definitively determine clinical utility of this treatment.